Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
复制标题
DOI：
10.1136/thorax.2003.012658
复制
发表时间：
2004-03-01
期刊：
影响因子：
10
通讯作者：
Yuen, KY
中科院分区：
文献类型：
--
作者：
Chu, CM;Cheng, VCC;Yuen, KY
背景：在确定 SARS 相关冠状病毒对一组抗病毒药物的体外抗病毒敏感性后，检查了严重急性呼吸综合征 (SARS) 患者对洛匹那韦/利托那韦和利巴韦林联合用药的临床反应。方法：SARS 相关冠状病毒原型对一组核苷的体外敏感性 对目前许可用于临床的类似物和蛋白酶抑制剂进行了研究。 41 名 SARS 患者接受了 3 周的洛匹那韦/利托那韦和利巴韦林联合治疗。对临床进展和病毒学结果进行了监测，并与作为历史对照的 111 名仅接受利巴韦林治疗的患者进行了比较。结果：洛匹那韦和利巴韦林在浓度分别为 4 微克/毫升和 50 毫克/毫升的情况下仅在 48 小时内就显示出针对 SARS 相关冠状病毒的体外抗病毒活性。治疗组的不良临床结果（ARDS 或死亡）显着低于历史对照组（2.4% vs 28.8%，p
Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral susceptibility of the SARS associated coronavirus to a panel of antiviral agents.Methods: The in vitro susceptibility of the prototype of SARS associated coronavirus to a panel of nucleoside analogues and protease inhibitors currently licensed for clinical use was studied. Forty one patients with SARS followed for 3 weeks were treated with a combination of lopinavir/ritonavir and ribavirin. The clinical progress and virological outcomes were monitored and compared with 111 patients treated with ribavirin only who served as historical controls.Results: In vitro antiviral activity against SARS associated coronavirus was demonstrated for lopinavir and ribavirin at concentrations of 4 mug/ml and 50 mg/ml, respectively, only at 48 hours. The adverse clinical outcome (ARDS or death) was significantly lower in the treatment group than in the historical controls (2.4% v 28.8%, p